Gane E. Safety and Efficacy at 1 year after Switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use. PS-156.
Maarten Schim van der Loeff hoogleraar Epidemiologie van seksueel overdraagbare infecties
jun 2020 | SOA